Login / Signup

Successful treatment of idiopathic Harlequin Syndrome with oxybutynin and propranolol.

Cristina Naharro-FernándezAdrián de Quintana-SanchoAna Elizabet López-SundhLeandra Reguero-Del CuraMarcos A González-López
Published in: The Australasian journal of dermatology (2021)
Harlequin syndrome (HS) is a rare entity derived from the dysfunction of the sympathetic nervous system. It is characterised by unilateral facial flushing and sweating induced by exercise, heat and emotion. Most cases are primary with an unknown pathogenic mechanism. In these cases, the prognosis is favourable. Medical or surgical treatments are not usually required for idiopathic HS. However, symptomatic treatment may be indicated when symptoms affect the quality of life of patients. We present the case of a patient with idiopathic HS successfully treated with oxybutynin and propranolol. In this patient, a marked improvement in both hyperhidrosis and facial erythema was noted with this combined therapy. We consider it of interest to highlight the response of our patient to the treatment employed, which may be advantageous in future cases of this rare disorder.
Keyphrases
  • case report
  • end stage renal disease
  • healthcare
  • chronic kidney disease
  • ejection fraction
  • depressive symptoms
  • oxidative stress
  • stem cells
  • soft tissue
  • bone marrow
  • combination therapy
  • patient reported outcomes